Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer

International Journal of Biological Markers

Volumn 19, Issue 2, 2004, Pages 130-134

  Berberoglu, Ugur ^a,b   Yildirim, E ^a   Celen, O ^a  

^a Ankara Oncology Teaching and Research Hospital   (Turkey)

^b Mesa Koru Sitesi   (Turkey)

Author keywords

Locally advanced breast cancer; Neoadjuvant chemotherapy; TNF

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPIRATION BIOPSY; BLOOD SAMPLING; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MASTECTOMY; OUTCOMES RESEARCH; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 4243061787     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080401900207     Document Type: Article

References (18)

1. Arai K, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Ann Res Biochem 1990; 59: 783-836.
2. Balkwill FE, Burke F. The cytokine network. Immunol Today 1989; 10: 299-304.
3. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
4. Vilcek J, Palombella VJ, Henriksen D, et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1985; 163: 632-8.
5. Agroyannis J, Kouvaris J, Tzanatos H, et al. Influence of radiation treatment on serum transferring and tumor necrosis factor-α. Anticancer Res 1992; 12: 1757-60.
6. Chen MS, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997; 43: 211-5.
7. Beksaç M, Ertürk Ş, Akan H, Koç H, Ilhan O. The clinical correlation of serum tumor necrosis factor-alpha in acute leukemias: A predictor of response and relapse? Leukemia 1993; 7: 1773-6.
8. Barok V, Nisman B, Polliak A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol 1999; 62: 171-5.
9. Mallmann P, Diedrich K, Mallmann R, Koenig UD, Krebs D. Determination of TNF alpha, interferon alpha, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients. Anticancer Res 1991; 11: 1509-16.
10. Ocvirk J, Stabuc B, Rudolf Z, Galvani V, Serbec V. Serum values of tumor necrosis factor-alpha and soluble tumor necrosis factor-R55 in melanoma patients. Melanoma Res 2000; 10: 253-8.
11. Ardizzoia A, Lissoni P, Brivio F, et al. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 1992; 6: 103-7.
12. Warzocha K, Bienvenu J, Ribeiro P, et al. Plasma levels of tumor necrosis factor and its soluble receptor correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 1998; 77: 2357-62.
13. Tesarova P, Kvasnicka J, Umlaufova A, Homolkova H, Jirsa M, Tesa V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 2000; 6: 661-7.
14. Jablonska E, Kiluk M, Markiewicz W. Soluble TNF receptors release by polymorphonuclear cells and the serum levels in breast cancer patients before and after treatment. Neoplasma 1998; 45: 17-20.
15. Aderka D, Engelmann H, Honik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991; 51: 5602-7.
16. Langkopt F, Atzopdien J. Soluble tumor necrosis factor receptors as prognostic factor in cancer patients. Lancet 1994; 344: 57-8.
17. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002; 87: 21-7.
18. Jablonska E. Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment. Cytokine 1998; 10: 540-3.